TRVI News and Press, Trevi Therapeutics Inc. From 08/12/21

Trevi Therapeutics Announces Second Quarter 2021 Financial Results and Business Update Phase 2b/3 PRISM (Chronic Pruritus in PN) Trial Approximately 80% Enrolled, Top-Line Data Readout Expected First Half of 2022 Phase 2 CANAL (Chronic Cough in IPF) Trial Recruiting, Top-Lin...

Trevi Therapeutics Announces Additions to the Senior Leadership Team Key Management Appointments Support Company Growth as Lead Trials Move Towards Data PR Newswire NEW HAVEN, Conn. , Aug. 9, 2021 /PRNewswire/ -- Trevi Therapeutics, Inc. (Nasdaq: TRVI), a...

Trevi Therapeutics to Report Q2 2021 Financial Results on August 12 Conference Call and Webcast to be Held at 4:30 p.m. ET PR Newswire NEW HAVEN, Conn. , Aug. 5, 2021 /PRNewswire/ -- Trevi Therapeutics, Inc. (Nasdaq: TRVI), a clinical-stage biopharmac...

Trevi Therapeutics to Present at 2021 BIO Digital Conference PR Newswire NEW HAVEN, Conn. , June 9, 2021 /PRNewswire/ -- Trevi Therapeutics, Inc. (Nasdaq: TRVI), a clinical-stage biopharmaceutical company focused on the development and commercialization of th...

Trevi Therapeutics, Inc. (TRVI) Q1 2021 Earnings Conference Call May 13, 2021 4:30 PM ET Company Participants Jennifer Good – President and Chief Executive Officer Bill Forbes – Chief Development Officer Conference Call Participants Annabel Samimy – Stifel Gary Nachman &#...

Trevi Therapeutics Announces First Quarter 2021 Financial Results and Business Update Phase 2b/3 PRISM (Chronic Pruritus in PN) Trial Over 70% Enrolled Phase 2 CANAL (Chronic Cough in IPF) Trial Resumes Screening at Multiple Sites Fast Track Designation Granted by FDA fo...

Trevi Therapeutics to Report Q1 2021 Financial Results on May 13 Conference Call and Webcast to be Held at 4:30 p.m. ET PR Newswire NEW HAVEN, Conn. , May 6, 2021 /PRNewswire/ -- Trevi Therapeutics, Inc. (NASDAQ: TRVI), a clinical-stage biopharmaceutical ...

NEW HAVEN, Conn., April 07, 2021 (GLOBE NEWSWIRE) -- Trevi Therapeutics, Inc. (Nasdaq: TRVI), a clinical-stage biopharmaceutical company focused on the development and commercialization of Haduvio™ (nalbuphine ER) to treat serious neurologically mediated conditions, today announced t...

Trevi Therapeutics, Inc. (TRVI) Q4 2020 Earnings Conference Call March 25, 2021 4:30 PM ET Company Participants Jennifer Good - President and CEO Chris Seiter - Chief Financial Officer Bill Forbes - Chief Development Officer Conference Call Participants Gary Nachman - BMO Capital Markets Anna...

Expects to Complete Enrollment and Report Top-Line Data of the Phase 2b/3 PRISM Trial in Second Half of 2021 Cash Position Expected to Fund Operations into the Second Quarter of 2022 NEW HAVEN, Conn., March 25, 2021 (GLOBE NEWSWIRE) -- Trevi Therapeutics, Inc. (Nasdaq: TRV...